2021
Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
Babitt J, Eisenga M, Haase V, Kshirsagar A, Levin A, Locatelli F, Małyszko J, Swinkels D, Tarng D, Cheung M, Jadoul M, Winkelmayer W, Drüeke T, Participants C, Abu-Alfa A, Afsar B, Pai A, Besarab A, Moore G, Casadevall N, Cases A, de Francisco A, Eckardt K, Fishbane S, Fried L, Ganz T, Ginzburg Y, Gómez R, Goodnough L, Hamano T, Hanudel M, Hao C, Iseki K, Ix J, Johansen K, Ketteler M, Kovesdy C, Leaf D, Macdougall I, Massy Z, McMahon L, Minutolo R, Nakanishi T, Nemeth E, Obrador G, Parfrey P, Park H, Pecoits-Filho R, Robinson B, Roger S, Shah Y, Spinowitz B, Tanaka T, Tsukamoto Y, Tungsanga K, Walther C, Wang A, Wolf M. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International 2021, 99: 1280-1295. PMID: 33839163, DOI: 10.1016/j.kint.2021.03.020.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseAnemia guidelinesHypoxia-inducible factor prolyl hydroxylase inhibitorOptimal anemia managementErythropoiesis-stimulating agentsTreatment of anemiaIron homeostasisSignificant adverse consequencesControversies ConferenceIron therapyAnemia managementRandomized trialsDiagnostic challengePatient outcomesEpidemiological studiesHydroxylase inhibitorTreatment targetsGlobal outcomeLatest evidenceDiseaseAnemiaPrevious recommendationsAdverse consequencesOngoing controversy
2008
The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis*
Abu-Alfa AK, Sloan L, Charytan C, Sekkarie M, Scarlata D, Globe D, Audhya P. The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis*. Current Medical Research And Opinion 2008, 24: 1091-1100. PMID: 18328118, DOI: 10.1185/030079908x280653.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseErythropoiesis-stimulating agentsHealth-related qualityDarbepoetin alfaWeek 52Week 12Kidney diseasePatients' health-related qualityGeneral CKD populationQ2W darbepoetin alfaWeek darbepoetin alfaGlomerular filtration rateSingle-arm studyBenefits of treatmentMean Hb concentrationYears of ageSubject inclusion criteriaCKD populationCreatinine clearanceHemoglobin levelsHb targetHb levelsHRQOL measuresFiltration rateInclusion criteria
2000
Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients
Abu-Alfa A, Cruz D, Perazella M, Mahnensmith R, Simon D, Bia M. Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. American Journal Of Kidney Diseases 2000, 35: 1076-1082. PMID: 10845820, DOI: 10.1016/s0272-6386(00)70043-6.Peer-Reviewed Original ResearchMeSH KeywordsAnemiaAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBlood TransfusionCross-Over StudiesDiabetes ComplicationsDrug ResistanceEpoetin AlfaErythropoietinFemaleFollow-Up StudiesHematinicsHematocritHospitalizationHumansInfectionsKidney Failure, ChronicLisinoprilMaleMiddle AgedProspective StudiesRecombinant ProteinsRenal DialysisTime FactorsConceptsACE inhibitor therapyACE inhibitorsHemodialysis patientsRHuEPO resistanceInhibitor therapyRecombinant human erythropoietin resistanceRecombinant human erythropoietin (rHuEPO) requirementsBlood pressure controlChronic renal failureDuration of infectionRHuEPO doseTransfusion requirementsErythropoietin resistanceRenal failureDialysis patientsHospitalization daysLaboratory parametersRHuEPO dosesAntihypertensive agentsCrossover studyErythropoietin requirementsInclusion criteriaPatientsAverage ageEnzyme inhibitors